Vertex Pharmaceuticals Inc.’s cystic fibrosis drug Kalydeco (ivacaftor) demonstrated generally positive effects on a slew of secondary endpoints in two pivotal trials, and yet it remains a question mark how, and whether, some of these measures translate into clinical benefit.
During the course of their review, FDA staff raised questions about the clinical meaningfulness of changes in sweat chloride and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?